公开(公告)号：EP1387701A2

公开(公告)日：2004-02-11

申请号：EP02735057.8

申请日：2002-05-03

申请人： Bergter, Wolfgang, Dr. ,  Kobilke, Hartmut, Dr. ,  Sroka, Joachim

发明人： Bergter, Wolfgang, Dr. ,  Kobilke, Hartmut, Dr. ,  Sroka, Joachim

IPC分类号： A61K51/10 ,  A61K47/48 ,  A61K41/00 ,  A61K49/00

CPC分类号： B82Y5/00 ,  A61K41/0057 ,  A61K41/0071 ,  A61K47/6898 ,  A61K51/1006 ,  A61K51/1027 ,  A61K51/1036 ,  A61K51/1093

摘要： The invention relates to immunoconjugates made of egg-yolk antibodies (IgY), the production and use thereof in diagnoses and therapy. The aim of the invention is to provide alternative products to traditional immunoconjugates for use in diagnoses and therapy. The inventive immunoconjugates are superior to monoclonal antibodies and immune serums from mammals in addition to IgY preparations from conventional hens in terms of purity and antigen targeting. The invention seeks to avoid the formation of human anti-IgY antibodies as far as possible, and to produce immunoconjugates in large quantities at a low price in a manner which is compatible with animal welfare. This is achieved by polyclonal IgY conjugates from intact egg-yolk antibodies (IgY), IgY fragments, Fab constructions or humanized egg-yolk antibodies form SPF hens, preferably from transgenic SPF hens. The antibodies or antibody fragments are conjugated as immunologically effective components with at least one other component such as a signaling substance, an active substance or an amplifier module.

公开(公告)号：EP1387701B1

公开(公告)日：2004-10-27

申请号：EP02735057.8

申请日：2002-05-03

申请人： Bergter, Wolfgang, Dr. ,  Kobilke, Hartmut, Dr. ,  Sroka, Joachim

发明人： Bergter, Wolfgang, Dr. ,  Kobilke, Hartmut, Dr. ,  Sroka, Joachim

IPC分类号： A61K51/10 ,  A61K47/48 ,  A61K41/00 ,  A61K49/00

CPC分类号： B82Y5/00 ,  A61K41/0057 ,  A61K41/0071 ,  A61K47/6898 ,  A61K51/1006 ,  A61K51/1027 ,  A61K51/1036 ,  A61K51/1093

摘要： The invention relates to immunoconjugates made of egg-yolk antibodies (IgY), the production and use thereof in diagnoses and therapy. The aim of the invention is to provide alternative products to traditional immunoconjugates for use in diagnoses and therapy. The inventive immunoconjugates are superior to monoclonal antibodies and immune serums from mammals in addition to IgY preparations from conventional hens in terms of purity and antigen targeting. The invention seeks to avoid the formation of human anti-IgY antibodies as far as possible, and to produce immunoconjugates in large quantities at a low price in a manner which is compatible with animal welfare. This is achieved by polyclonal IgY conjugates from intact egg-yolk antibodies (IgY), IgY fragments, Fab constructions or humanized egg-yolk antibodies form SPF hens, preferably from transgenic SPF hens. The antibodies or antibody fragments are conjugated as immunologically effective components with at least one other component such as a signaling substance, an active substance or an amplifier module.

摘要翻译： 本发明涉及由蛋黄抗体（IgY）制成的免疫缀合物，其在诊断和治疗中的生产和用途。 本发明的目的是提供用于诊断和治疗的传统免疫缀合物的替代产品。 就纯度和抗原靶向而言，除了来自传统母鸡的IgY制剂外，本发明的免疫缀合物优于来自哺乳动物的单克隆抗体和免疫血清。 本发明试图尽可能避免形成人抗IgY抗体，并且以与动物福利相容的方式以低价大量生产免疫缀合物。 这通过来自完整蛋黄抗体（IgY），IgY片段，Fab构建体或人源化蛋黄抗体的多克隆IgY缀合物形成SPF母鸡，优选来自转基因SPF母鸡。 抗体或抗体片段作为免疫学有效成分与至少一种其他组分例如信号物质，活性物质或放大器模块缀合。

公开(公告)号：EP1299420A2

公开(公告)日：2003-04-09

申请号：EP01956306.3

申请日：2001-07-05

申请人： Bergter, Wolfgang ,  Kobilke, Hartmut

发明人： KOBILKE, Hartmut

IPC分类号： C07K16/02 ,  A61K39/395 ,  A61K31/65 ,  A61K31/355 ,  A61K31/375 ,  A61K7/48 ,  A61K47/44

CPC分类号： C07K16/12 ,  A61K35/748 ,  A61K39/40 ,  A61K2039/505 ,  C07K2317/11 ,  A61K2300/00

摘要： The invention relates to a composition for pharmaceutical and cosmetic products in addition to the use thereof for treating injuries, particularly in cases of persistent and acute chronical inflammation, by administration of said inventive composition comprising immunoglobulin. The inventive composition is characterised in that the fundamental active component is Ig Y in egg yolks (mono- or polyvalent) from SPF chickens, micro algae extracts, preferably from the spirulina and chlorella variety, with or without oxytetracycline. Said composition can be used by humans and animals in liquid, paste or solid form, particularly as a cream, oil, liquid plaster, aerosol or in tablets or powder.

公开(公告)号：EP1299420B1

公开(公告)日：2008-02-13

申请号：EP01956306.3

申请日：2001-07-05

申请人： Bergter, Wolfgang, Dr. ,  Kobilke, Hartmut, Dr. ,  Sroka, Joachim

发明人： KOBILKE, Hartmut

IPC分类号： C07K16/02 ,  A61K39/395 ,  A61K31/65 ,  A61K31/355 ,  A61K31/375 ,  A61K8/00

CPC分类号： C07K16/12 ,  A61K35/748 ,  A61K39/40 ,  A61K2039/505 ,  C07K2317/11 ,  A61K2300/00

摘要： The invention relates to a composition for pharmaceutical and cosmetic products in addition to the use thereof for treating injuries, particularly in cases of persistent and acute chronical inflammation, by administration of said inventive composition comprising immunoglobulin. The inventive composition is characterised in that the fundamental active component is Ig Y in egg yolks (mono- or polyvalent) from SPF chickens, micro algae extracts, preferably from the spirulina and chlorella variety, with or without oxytetracycline. Said composition can be used by humans and animals in liquid, paste or solid form, particularly as a cream, oil, liquid plaster, aerosol or in tablets or powder.

公开(公告)号：EP1091763B1

公开(公告)日：2003-09-17

申请号：EP99941408.9

申请日：1999-06-29

申请人： Bergter, Wolfgang

发明人： Bergter, Wolfgang

IPC分类号： A61K51/10 ,  A61P31/12

CPC分类号： A61K51/1006 ,  A61K51/1027 ,  A61K51/1093

摘要： The invention relates to a pharmaceutical preparation comprising a radioimmunological conjugate (RIK) for in-vivo elimination of virus-replicating cells in HIV-1, HIV-2, HIV-3, HTLV-1, HTLV-2, HBV, HCV, HDV, CMV, EBV, HHV8 infections and in other chronic virus infections. The radioimmunological conjugate is characterized in that it contains, as immunologically effective constituents; d) a monoclonal antibody or the antigen-binding fragment thereof against a viral or virus-induced antigen expressed on the plasma membrane of virus-infected cells, or; e) a receptor molecule or the fragment thereof with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells; or f) a fragment of the cellular receptor molecule, said fragment being modified by mutagenesis, with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells. Said conjugate is also characterized in that it contains d) an alpha emitter or a beta emitter as a radioactive constituent. The inventive pharmaceutical preparation also optionally comprises a pharmaceutical carrier and/or adjuvant.

公开(公告)号：EP1091763A2

公开(公告)日：2001-04-18

申请号：EP99941408.9

申请日：1999-06-29

申请人： Bergter, Wolfgang

发明人： Bergter, Wolfgang

IPC分类号： A61K51/10 ,  A61P31/12

CPC分类号： A61K51/1006 ,  A61K51/1027 ,  A61K51/1093

摘要： The invention relates to a pharmaceutical preparation comprising a radioimmunological conjugate (RIK) for in-vivo elimination of virus-replicating cells in HIV-1, HIV-2, HIV-3, HTLV-1, HTLV-2, HBV, HCV, HDV, CMV, EBV, HHV8 infections and in other chronic virus infections. The radioimmunological conjugate is characterized in that it contains, as immunologically effective constituents; d) a monoclonal antibody or the antigen-binding fragment thereof against a viral or virus-induced antigen expressed on the plasma membrane of virus-infected cells, or; e) a receptor molecule or the fragment thereof with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells; or f) a fragment of the cellular receptor molecule, said fragment being modified by mutagenesis, with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells. Said conjugate is also characterized in that it contains d) an alpha emitter or a beta emitter as a radioactive constituent. The inventive pharmaceutical preparation also optionally comprises a pharmaceutical carrier and/or adjuvant.

公开(公告)号：EP1071475A2

公开(公告)日：2001-01-31

申请号：EP99927685.0

申请日：1999-04-15

申请人： Bergter, Wolfgang ,  Bergter, Ingrid-Corina

发明人： Bergter, Wolfgang ,  Bergter, Ingrid-Corina

IPC分类号： A61K51/08

CPC分类号： A61K51/08

摘要： The disadvantages of standard HIV therapies are as follows: currently used medicaments must be taken in large quantities each day during an entire lifetime according to a strict timetable and have a large number of side effects. Traditional medicaments only manage to restrict virus replication. Host cells infected with HIV are not eliminated. For this reason it was not previously possible to cure HIV infections. The current application describes, as an additional application to PCT patent application (PCT/DE99/00598) dated 8.3.99, radio-immunological pharmaceuticals consisting of a CD4 molecule or a fragment derived therefrom and a radionuclide for in-vivo elimination of HIV replicating cells in HIV-1 and HIV-2 infected patients. The combination of HIV affine CD4 receptor molecules or fragments with radionuclides for therapeutic purposes, especially for use in radioimmunological anti-HIV therapy is totally novel. The radioimmunological pharmaceuticals are to be administered intravenously to HIV-1 or HIV-2 infected patients once or in several cycles in order to cause sustained damage to HIV replicating cells in a targeted manner so that the latter can be fully eliminated.

公开(公告)号：EP1061959A2

公开(公告)日：2000-12-27

申请号：EP99919038.2

申请日：1999-03-05

申请人： Bergter, Wolfgang ,  Bergter, Ingrid-Corina

发明人： Bergter, Wolfgang ,  Bergter, Ingrid-Corina

IPC分类号： A61K51/10

CPC分类号： A61K51/1039

摘要： The invention relates to the use of a radioimmuno-conjugate for eliminating virus-replicating cells in vivo in HIV-infected patients. The radioimmuno-conjugate contains an immunologically effective component in the form of a human or murine, optionally humanised monoclonal antibody against an epitope on the surface glycoprotein gp120 or the transmembrane glycoprotein gp41 of HIV-1, together with pharmaceutical excipients and/or adjuvants, and a radioactive component in the form of e.g., 131J, 32P, 90 Y, 89 Sr. The radioimmuno-conjugate is used whilst the viral burden is being reduced or after it has been reduced by means of an antiretroviral standard triple therapy.